IN THE CLAIMS:

Please cancel claims 29 and 30, and amend claim 16, as shown below in the detailed listing of all claims which are, or were, in the application:

Claims 1-15 (canceled).

16. (Currently amended) A method for treatment of a local inflammatory disease or disorder, comprising

administering to a person or animal in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable agent or salt thereof capable of acidifying cell cytoplasm, said agent being an acid having a dissociation constant in the range of 6.7 to 7.4,

wherein an effective amount of said agent is administered in ${\tt non-dissociated}$ form to said person or animal, ${\tt and}$

wherein said agent is mixed with a carrier to adjust the pH of said composition to a pH range of 6.1 to 7.0, and

wherein the agent comprises an organic acid having a heterocyclic ring selected from the group consisting of imidazole,

thiazole, thiophene, furan, oxazole, triazole, tetrazole, pyrazole,

pyridine, pyrimidine and triazine.

17. (Canceled)

18. (Canceled)

19. (Previously presented) The method of claim 16, wherein said reaction involves activation of cells of innate immune system.

20. (Previously presented) The method of claim 19, wherein said reaction is a member of the group consisting of contact hypersensitivity reactions, delayed type hypersensitivity reactions, acute graft rejection, psoriasis, dermatitis, periodontitis, mastitis, and vasculitis.

- 21. (Previously presented) The method of claim 16, wherein the agent is administered systemically or locally.
- 22. (Previously presented) The method of claim 21, where said agent is administered locally.

U.S. Patent Appln. S.N. 10/534,988 AMENDMENT AFTER FINAL REJECTION PATENT

Claims 23-27 (Canceled).

- 28. (Previously presented) The method according to claim 16, wherein the agent is cis-urocanic acid.
- 29. (Canceled).
- 30. (Canceled).